A nasal CGRP receptor antagonist for acute migraine therapy
A nasal CGRP receptor antagonist for acute migraine therapy
About this item
Full title
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Zavegepant, the first nasal formulation of a calcitonin gene-related peptide (CGRP) receptor antagonist, or gepant, has passed the final stage of its developmental programme as an acute migraine therapy, and is now being considered for regulatory approval in the USA.1 In The Lancet Neurology, Richard B Lipton and colleagues report the findings from...
Alternative Titles
Full title
A nasal CGRP receptor antagonist for acute migraine therapy
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2778973066
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2778973066
Other Identifiers
ISSN
1474-4422
E-ISSN
1474-4465
DOI
10.1016/S1474-4422(23)00037-6
